



NEWS RELEASE

Contacts: Celeste Speier, Beckman Coulter, Inc.
Phone: (714) 993-8955
E-mail: cmspeier@beckman.com

Steve Ernst, Veris Communications
Phone: (973) 702-7249
E-mail: veriscomm@gmail.com

FOR IMMEDIATE RELEASE

Cogenics Announces Global Availability of Standardized and Cost-Efficient Drug Metabolizing Enzymes and Transporters (DMET) Analysis Service

Pharmacogenetic Test Examines More Than 1,900 Markers

BEVERLY, Mass. -- (May 28, 2009) — Cogenics, a Beckman Coulter company, introduces a new global service for its pharma partners that uses the DMET (Drug Metabolizing Enzymes and Transporters) Plus Premier Pack* from Affymetrix, Inc. to simultaneously examine 1,936 drug metabolism markers in 225 genes. The panel features markers for all FDA-validated genes and covers more than 90 percent of the current ADME Core Markers as defined by the PharmaADME group.

The new service applies the recently released DMET Plus Premier Pack for standardized, cost-efficient drug safety-related testing in clinical trials. Cogenics, the first company to offer this service globally, delivers the high quality data associated with pharmacogenetic testing by combining DMET microarray and other genotyping data using their world-class bioinformatics capabilities.

Cogenics collaborated with both Affymetrix and Eli Lilly in the development of the previously released DMET Early Access Kit. As a first provider of services based on these initial kits, the company acquired extensive experience with DMET testing and has analyzed nearly 4,000 customer samples.

“Given our experience and success with the DMET platform, we’re excited to make this new solution available to our pharma customers,” said Susan Evans, global general manager, Cogenics and Agencourt. “We will provide clients with superior genotyping data in a cost-efficient manner.”

Pharmacogenetics testing has become a routinely used process during drug development, with a particular focus on DMET-related testing during clinical drug development.

“Cogenics has a well-established reputation for providing high quality genomic services in the U.S. and Europe. We’re very happy to be part of this expanded global service using our DMET Plus Premier Pack,” said Kevin King, Affymetrix CEO and president. “Using this new offering, pharma customers will be able to identify the high-quality biomarkers that will enable them to ask broader questions and make better ‘go/no-go’ clinical trial decisions.”

About Beckman Coulter, Inc.

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of \$3.1 billion. For more information, visit www.beckmancoulter.com.

Cogenics is a leading global genomic service provider with more than 25 years of experience in pharmacogenetic testing. To date, the company has analyzed/genotyped more than 150,000 samples in support of over 2000 clinical trials. Cogenics was acquired by Beckman Coulter, Inc. in April 2009 to be merged with Agencourt Bioscience Corp. With facilities across the U.S. and Europe, the combined company also offers

proven experience and expertise for genomics services in the fields of Sanger and next-gen sequencing, gene expression, biologics efficacy and safety testing, and sample management/extraction and biobanking. For more information please visit www.cogenics.com or www.agencourt.com.

*Trademarks are property of their respective owners.

#

Link to this release at:

Please send READER INQUIRIES from this news release directly to Beckman Coulter, c/o K. Delgado, Harte Hanks, 1753 South Pointe Avenue, Ontario, CA 91761. Or e-mail to k_delgado@harte-hanks.com.